Drug intelligence / Profile preview

bendamustine + gemcitabine

Development stage: Unknown
Lead developer: Teva Pharmaceutical Industries
Modality: Small Molecules
Administration: Intravenous

Overview

Bendamustine + gemcitabine is a chemotherapy combination regimen used as a salvage therapy for patients with recurrent/refractory Hodgkin lymphoma. This doublet has demonstrated efficacy with an overall response rate of 69% and complete response rate of 46% in phase 2 clinical trials. The recommended phase 2 dose is gemcitabine 1000 mg/m² on day 1 and bendamustine 120 mg/m² on days 1 and 2, administered every 21 days for up to 6 cycles. While effective, patients must be monitored closely for pulmonary toxicity, as grade 3-5 pulmonary adverse events have been reported in clinical trials.

Targets

DNARNR (Ribonucleotide reductase)

Beyond the preview

Go deeper on bendamustine + gemcitabine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on bendamustine + gemcitabine.

Explore the full profile